Clinical Trial Update: A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure [Phase 2]

View source ↗

Summary

Phase 2 dose-defining study of CXL-1020 in patients with systolic heart failure has completed, reporting phase 2 results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• CXL-1020

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Heart Failure | Phase 2 | Status: COMPLETED